These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30185673)

  • 1. Guaiacol as a drug candidate for treating adult polyglucosan body disease.
    Kakhlon O; Ferreira I; Solmesky LJ; Khazanov N; Lossos A; Alvarez R; Yetil D; Pampou S; Weil M; Senderowitz H; Escriba P; Yue WW; Akman HO
    JCI Insight; 2018 Sep; 3(17):. PubMed ID: 30185673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GYS1 or PPP1R3C deficiency rescues murine adult polyglucosan body disease.
    Chown EE; Wang P; Zhao X; Crowder JJ; Strober JW; Sullivan MA; Xue Y; Bennett CS; Perri AM; Evers BM; Roach PJ; Depaoli-Roach AA; Akman HO; Pederson BA; Minassian BA
    Ann Clin Transl Neurol; 2020 Nov; 7(11):2186-2198. PubMed ID: 33034425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Gys1 with AAV-SaCas9 Decreases Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models.
    Gumusgoz E; Guisso DR; Kasiri S; Wu J; Dear M; Verhalen B; Nitschke S; Mitra S; Nitschke F; Minassian BA
    Neurotherapeutics; 2021 Apr; 18(2):1414-1425. PubMed ID: 33830476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAV-Mediated Artificial miRNA Reduces Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models.
    Gumusgoz E; Kasiri S; Guisso DR; Wu J; Dear M; Verhalen B; Minassian BA
    Neurotherapeutics; 2022 Apr; 19(3):982-993. PubMed ID: 35347645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency.
    Nitschke S; Sullivan MA; Mitra S; Marchioni CR; Lee JPY; Smith BH; Ahonen S; Wu J; Chown EE; Wang P; Petković S; Zhao X; DiGiovanni LF; Perri AM; Israelian L; Grossman TR; Kordasiewicz H; Vilaplana F; Iwai K; Nitschke F; Minassian BA
    Brain; 2022 Jul; 145(7):2361-2377. PubMed ID: 35084461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alleviation of a polyglucosan storage disorder by enhancement of autophagic glycogen catabolism.
    Kakhlon O; Vaknin H; Mishra K; D'Souza J; Marisat M; Sprecher U; Wald-Altman S; Dukhovny A; Raviv Y; Da'adoosh B; Engel H; Benhamron S; Nitzan K; Sweetat S; Permyakova A; Mordechai A; Akman HO; Rosenmann H; Lossos A; Tam J; Minassian BA; Weil M
    EMBO Mol Med; 2021 Oct; 13(10):e14554. PubMed ID: 34486811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyglucosan neurotoxicity caused by glycogen branching enzyme deficiency can be reversed by inhibition of glycogen synthase.
    Kakhlon O; Glickstein H; Feinstein N; Liu Y; Baba O; Terashima T; Akman HO; Dimauro S; Lossos A
    J Neurochem; 2013 Oct; 127(1):101-13. PubMed ID: 23607684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel image-based high-throughput screening assay discovers therapeutic candidates for adult polyglucosan body disease.
    Solmesky LJ; Khazanov N; Senderowitz H; Wang P; Minassian BA; Ferreira IM; Yue WW; Lossos A; Weil M; Kakhlon O
    Biochem J; 2017 Sep; 474(20):3403-3420. PubMed ID: 28827282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adult polyglucosan body disease: proton magnetic resonance spectroscopy of the brain and novel mutation in the GBE1 gene.
    Massa R; Bruno C; Martorana A; de Stefano N; van Diggelen OP; Federico A
    Muscle Nerve; 2008 Apr; 37(4):530-6. PubMed ID: 17994551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design.
    Froese DS; Michaeli A; McCorvie TJ; Krojer T; Sasi M; Melaev E; Goldblum A; Zatsepin M; Lossos A; Álvarez R; Escribá PV; Minassian BA; von Delft F; Kakhlon O; Yue WW
    Hum Mol Genet; 2015 Oct; 24(20):5667-76. PubMed ID: 26199317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal Muscle Glycogen Chain Length Correlates with Insolubility in Mouse Models of Polyglucosan-Associated Neurodegenerative Diseases.
    Sullivan MA; Nitschke S; Skwara EP; Wang P; Zhao X; Pan XS; Chown EE; Wang T; Perri AM; Lee JPY; Vilaplana F; Minassian BA; Nitschke F
    Cell Rep; 2019 Apr; 27(5):1334-1344.e6. PubMed ID: 31042462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surprises of genetic engineering: a possible model of polyglucosan body disease.
    Raben N; Danon M; Lu N; Lee E; Shliselfeld L; Skurat AV; Roach PJ; Lawrence JC; Musumeci O; Shanske S; DiMauro S; Plotz P
    Neurology; 2001 Jun; 56(12):1739-45. PubMed ID: 11425943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel mouse model that recapitulates adult-onset glycogenosis type 4.
    Orhan Akman H; Emmanuele V; Kurt YG; Kurt B; Sheiko T; DiMauro S; Craigen WJ
    Hum Mol Genet; 2015 Dec; 24(23):6801-10. PubMed ID: 26385640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GBE1-related disorders: Adult polyglucosan body disease and its neuromuscular phenotypes.
    Souza PVS; Badia BML; Farias IB; Pinto WBVR; Oliveira ASB; Akman HO; DiMauro S
    J Inherit Metab Dis; 2021 May; 44(3):534-543. PubMed ID: 33141444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triacylglycerol mimetics regulate membrane interactions of glycogen branching enzyme: implications for therapy.
    Alvarez R; Casas J; López DJ; Ibarguren M; Suari-Rivera A; Terés S; Guardiola-Serrano F; Lossos A; Busquets X; Kakhlon O; Escribá PV
    J Lipid Res; 2017 Aug; 58(8):1598-1612. PubMed ID: 28630259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene.
    Lossos A; Meiner Z; Barash V; Soffer D; Schlesinger I; Abramsky O; Argov Z; Shpitzen S; Meiner V
    Ann Neurol; 1998 Dec; 44(6):867-72. PubMed ID: 9851430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myofiber-type-dependent 'boulder' or 'multitudinous pebble' formations across distinct amylopectinoses.
    Mitra S; Chen B; Shelton JM; Nitschke S; Wu J; Covington L; Dear M; Lynn T; Verma M; Nitschke F; Fuseya Y; Iwai K; Evers BM; Minassian BA
    Acta Neuropathol; 2024 Feb; 147(1):46. PubMed ID: 38411740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal glycogen in astrocytes is sufficient to cause adult polyglucosan body disease.
    Dainese L; Monin ML; Demeret S; Brochier G; Froissart R; Spraul A; Schiffmann R; Seilhean D; Mochel F
    Gene; 2013 Feb; 515(2):376-9. PubMed ID: 23266647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel GBE1 mutation and features of polyglucosan bodies autophagy in adult polyglucosan body disease.
    Sampaolo S; Esposito T; Gianfrancesco F; Napolitano F; Lombardi L; Lucà R; Roperto F; Di Iorio G
    Neuromuscul Disord; 2015 Mar; 25(3):247-52. PubMed ID: 25544507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic investigations of adult polyglucosan body disease: insights into the pathobiology of a neurodegenerative disorder.
    Abraham JR; Allen FM; Barnard J; Schlatzer D; Natowicz MR
    Front Neurol; 2023; 14():1261125. PubMed ID: 38033781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.